2. Academic Validation
  3. CXCL9: evidence and contradictions for its role in tumor progression

CXCL9: evidence and contradictions for its role in tumor progression

  • Cancer Med. 2016 Nov;5(11):3246-3259. doi: 10.1002/cam4.934.
Qiang Ding 1,  Panpan Lu 1,  Yujia Xia 1,  Shuping Ding 1,  Yuhui Fan 1,  Xin Li 1,  Ping Han 1,  Jingmei Liu 1,  Dean Tian 1,  Mei Liu 1
Affiliations

Affiliation

  • 1 Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, 430030, China.
PMID: 27726306 DOI: 10.1002/cam4.934
Abstract

Chemokines are a group of low molecular weight Peptides. Their major function is the recruitment of leukocytes to inflammation sites, but they also play a key role in tumor growth, angiogenesis, and metastasis. In the last few years, accumulated experimental evidence supports that monokine induced by interferon (IFN)-gamma (CXCL9), a member of CXC chemokine family and known to attract CXCR3- (CXCR3-A and CXCR3-B) T lymphocytes, is involved in the pathogenesis of a variety of physiologic diseases during their initiation and their maintenance. This review for the first time presents the most comprehensive summary for the role of CXCL9 in different types of tumors, and demonstrates its contradictory role of CXCL9 in tumor progression. Altogether, this is a useful resource for researchers investigating therapeutic opportunities for Cancer.

Keywords

CXCL9; Cancer; therapy; tumor promoter; tumor suppressor.

Figures
Products